SpringerProtocols: Abstract: Continuous Infusion of Antisense Phosphorothioate Therapeutics

Continuous Infusion of Antisense Phosphorothioate Therapeutics

By: Patrick L. Iversen², Bryan L. Copple², Hemant K. Tewary², Eliel Bayever³, Michael R. Bishop⁴

Abstract

Full Text

Download PDF (7570K)

Current therapy for acute myelogenous leukemia (AML) includes induction with Ara-C and an anthracycline, such as daunorubicin, idarubicin, or mitoxantrone. Unfortunately, most patients relapse from initial remission. Nearly one-fifth of early relapses experience treatment-related deaths. In addition, patients refractory to Ara-C die within months. Hence, new therapeutic agents must be identified capable of enhanced remission rates, diminished treatment-related mortality, or that can achieve remissions in refractory patients.

Affiliation(s): (2) Departments of Pharmacology and Pharmaceutical Sciences, and The Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE
(3) Department of Hematology and Oncology, Children’s National Medical Center, Washington, DC
(4) Department of Internal Medicine, and The Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE

Book Title: Antisense Therapeutics

Series: Methods in Molecular Medicine | Volume: 1 | Pub. Date: Mar-25-1996 | Page Range: 201-212 | DOI: 10.1385/0-89603-305-8:201

Subject: Cell Biology

References

Download References

1.	Maltzman, W and Czyzyk, L(1984) UV irradiation stimulates levels of p53 cellular antigen in nontransformed mouse cells Mol. Cell Biol 4, 1689–1694.

2.	Kastan, M. B, Onyekwere, O, and Sidransky, D(1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51, 6304–6311

3.	Kastan, M. B, Zhan, Q, and El-Deiry, W. S(1992) A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in Ataxia-Telan-giectasia. Cell 71, 587–597

4.	Fritsche, M, Haessler, C, and Brandner, G(1993) Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 8, 307–318.

5.	Hall, P A., McKee, P. H, and Menage, H. P.(1993) High levels of p53 protein in UV-irradiated normal human skin. Oncogene 8, 203–207

6.	Tishler, R B, Calderwood, S. K, and Coleman, C N(1993) Increases in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents Cancer Res 53, 2212–2216

7.	Zhan, X, Carrier, F, and Fornace, A J, Jr(1993) Induction of cellular p53 activity by DNA-damaging agents and growth arrest Mol Cell Biol 13, 4242–4250

8.	Zhan, Q, Bae, I, and Kastan, M B(1994) The p53-dependent gamma-ray response of GADD45 Cancer Res 54, 2755–2760.

9.	Yonish-Rouach, E., Resnitzky, D., and Lotem, J(1991) Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin 6 Nature 352, 345–347.

10.	Shaw, P., Bovey, R, and Tardy, S.(1992) Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci USA 89, 4495–4499

11.	Ryan, J. J., Danish, R, and Gottlieb, C A.(1993) Cell cycle analysts of p53-induced cell death in murine erythroleukemia cells. Mol Cell Biol 13, 711–719.

12.	Hartwell, L H. and Wemert, T. A(1989) Checkpoints controls that ensure the order of cell cycle events. Science 246, 629–634.

13.	Hartwell, L.(1992) Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells Cell 71, 543–546.

14.	Kuerbitz, S. J, Plunkett, B S, and Walsh, W. V(1992) Weld-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89, 7491–7495.

15.	Tsuji, K and Ogawa, K. (1994) Recovery from ultraviolet-induced growth arrest of primary rat hepatocytes by p53 antisense oligonucleotide treatment Mol Carcinog 9, 167–174

16.	El-Deiry, W. S., Velculescu, T. T., and Levy, V. E(1993) WAF-1, a potential mediator of p53 tumor suppression. Cell 75, 817–825.

17.	Weinert, T A and Hartwell, L. H.(1988) The RAD9 gene controls the cell cycle response to DNA damage in Saccharomyces cerevisiae. Science 241, 317–322.

18.	Weinert, T A and Hartwell, L H.(1990) Characterization of RAD9 of Succharomyces cerevisiae and evidence that its function acts positranslationally in cell cycle arrest after DNA damage. Mol Cell Biol 10, 6554–6564

19.	McKirmon, P. J.(1987) Ataxia-telangiectasia: an inherited disorder of ionizingradiation sensitivity in man Hum. Genet 75, 197–208.

20.	Petty, R. D., Cree, I A., and Sutherland. L. A.(1994) Expression of the p53 tumor suppressor gene product is a determinant of chemosensitivity Biochem Biophys Res. Comm 199, 264–270

21.	Clarke, A R, Purdie, C A., and Harrison, D J.(1993) Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362, 849–852

22.	Lotem, J. and Sachs, L (1993) Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents Blood 82, 1092–1096

23.	Lowe, S. W., Schmitt, E. M., and Smith, S W.(1993) p53 is required for radianon-induced apoptosis in mouse thymocytes. Nature 362, 847–849

24.	O’Connor, P. M., Jackman, J, and Jondle, D.(1993) Role of p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkities Lymphoma cell lines. Cancer Res 53, 4776–4780

25.	Bayever, E., Haines, M, and Iversen, P. L(1994) Selective cytotoxicity to human leukemic myeloblasts produced by obgodeoxyribonucieotide phosphorothioates complementary to p53 nucleotide sequences Leukem Lymph 12, 223–231

26.	Koeffler, H P, Miller, C, and Nicolson, M A(1986) Increased expression of p53 protein in human leukemia cells. Proc. Natl Acad Sci USA 83, 4035–4039

27.	Smith, L J, McCulloch, E A, and Benchimol, S(1986) Expression of the p53 oncogene in acute myelogenous leukemia. J Exp. Med 164, 75l–761

28.	Sugimoto, K, Toyoshima, H, and Sakai, R.(1991) Mutations of the p53 gene in lymphoid leukemia. Blood 77, 1153–1156.

29.	Slingerland, J. M, Minden, M. D., and Benchimol, S(1991) Mutation of the p53 gene in human acute myelogenous leukemia Blood 77, 1500–1507

30.	Fenaux, P., Jonveaux, P, and Quiquandon, I.(1991) p53 gene mutations in myeloid leukemia with 17p monosomy. Blood 78, 1652–1657

31.	Stein, A., Iversen, P. L, Subasinghe, C., Cohen, J. S., Stec, W., and Zon, G. (1990) Preparation of ³⁵S-labelled polyphosphorothioate oligonucleotides by use of hydrogen phosphonate chemistry Anal Biochemistry 188, 11–16

32.	Srinivasan, S. K, Tewary, H. K., and Iversen, P. L.(1995) Phosphorothioate interactions with albumin and implications for potential drug interactions Antisense Res Dev, in press

33.	Koizumi, A, Walford, R L., and Imamura, T.(1986) Treatment with poly I. C enhances lipid peroxidation and the activity of xanthene oxidase, and decreases hepatic P-450 content and activities in mice and rats Biochem Biophys Res Commun. 134, 632–637

34.	Denis, D., Choo, L. Y., and Riendeau, D.(1989) Activation of 5-lipoxygenase by guanine 5’-0-(3thiotriphosphate) and other nucleoside phosphorothioates. redox properties of thionucleotide analogs. Arch Biochem. Biophys. 273, 592–596.

35.	Fidanza, J A and McLaughlin, L. W.(1989) Introduction of reporter groups at specific sites in DNA containing phosphorothioate diesters. J Am Chem Soc 111, 9117–9119

36.	Hodges, R R, Conway, N. E, and McLaughlin, L W(1989) Post-assay covalent labeling of phosphorothioate-containing nucleic acids with multiple fluorescent markers Biochemistry 28, 26l–267

37.	Conway, N E and McLaughlin, L W(1991) The covalent attachment of multrple fluorophores to DNA containing phosphorothioate diesters results in highly sensitive detection of single-stranded DNA. Bioconjugate Chem 2, 452–457.

38.	Ratajczak, M Z, Kant, J. A, Luger, S M, Hijiya, N., Zhang, J., Zon, G, and Gewirtz, A M.(1992) In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides Proc Natl Acad Sci USA 89, 11,823–l1,827

39.	Simmons, M, Edelman, E R, Dekyser, J-L, Langer, R, and Rosenberg, R D (1992) Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle accumulation in vivo Nature 359, 67–70

40.	Skorski, T, Nieborowska-Skorska, M, Nicolaides, N C, Szcylik, C, Iversen, P, Iozzo, R V, Zon, G, and Calabretta, B(1994) Suppression of Philadelphia leukemia cell growth in mice by bcr-abl antisense oligodeoxynucleotides Proc Natl Acad Sci USA 91, 4504–4508

41.	Agrawal, S, Temsamani, J, and Tang, J Y(1991) Pharmacokinetics, biodistribution and stability of oligodeoxynucleotide phosphorothioates in mice Proc Natl Acad Sci USA 88, 7595–7599

42.	Goodarzi, G, Watabe, M., and Watabe, K(1992) Organ distribution and stability of phosphorothioated oligodeoxyribonucleotides in mice Biopharm Drug Dispos 13, 22l–227

43.	Cossum, P A, Sasmor, H, Dellinger, D, Truong, L, Cummms, L, Owens, S R, Markham, P M, Shea, J P., and Crooke, S(1993) Disposition ofthe 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats J Pharmacol Exp Ther 267, 118l–l190

44.	Iversen, P L, Mata, J, Tracewell, W. G., and Zon, G.(1994) Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type I in the adult male rat following a single injections and continuous infusion Antisense Res Dev 4, 43–52

Comments (Loading...)

Post comment/View all comments